戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ay smooth muscles in the lung and acts as an antiasthmatic.
2 ihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepre
3 ents EIB in a dose-dependent manner; and its antiasthmatic activity is independent of its effect on p
4 such as montelukast or zafirlukast show good antiasthmatic activity over a wide spectrum of asthma se
5  has on the airway and whether its potential antiasthmatic activity would be similar to other PGEs.
6 iomer 16) and in vivo antihyperallodynic and antiasthmatic activity.
7 ch antagonists have therapeutic potential as antiasthmatic agents.
8                            Because PGE(2) is antiasthmatic and PGD(2) is proasthmatic, we speculate t
9 sought for their potential antiinflammatory, antiasthmatic, and antiischemic properties.
10         Other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiu
11 mediated metabolic perturbation, such as the antiasthmatic budesonide, blocked metastatic disseminati
12 riety of free aliphatic acids, including the antiasthmatic drug seratrodast, were compatible with the
13 acids of varying complexities, including the antiasthmatic drug seratrodast, were found to be compati
14                 Information on all dispensed antiasthmatic drugs (Anatomical Therapeutic Chemical cla
15 btained, and associations between the use of antiasthmatic drugs and the development of type 1 diabet
16               We examined whether the use of antiasthmatic drugs was associated with the development
17 of type 1 diabetes after adjusting for other antiasthmatic drugs, asthma, sex, and birth decade (haza
18  CysLT(1)R antagonists are currently used as antiasthmatic drugs, however, there are no approved drug
19  introduces the concept of disease-modifying antiasthmatic drugs, which aim to modify the course of a
20 ndergo the same developmental steps as other antiasthmatic drugs.
21 nd IL-13 and may be an attractive target for antiasthmatic drugs.
22 nosine receptor, which have the potential as antiasthmatic or antidiabetic drugs, we have synthesized
23 ght serve as a target for novel antiallergic/antiasthmatic therapies.
24  blocked by enprofylline (Ki = 7 microM), an antiasthmatic xanthine with low affinity (Ki > 100 micro
25                      The K(I) values for the antiasthmatic xanthines, theophylline (7.8 microM) and e